People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Other Technology, Biotech / Pharma, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Flywheel Exchange Inc. | — | Other Technology | Series C | $144.1M | $97.9M | 2017 |
| Gene Matters, LLC | — | Other Technology | Series A | $11.3M | $281.2M | 2017 |
| Invenshure LLC | — | Other Technology | Seed | $4.3M | $6.8M | 2011 |
| OneOme LLC | — | Other Technology | Seed | $3.8M | $3.4M | 2016 |
| Invenshure Fund I LP | — | Other Technology | Seed | $2.0M | $69.2M | 2012 |
| Imbio LLC | — | Other Technology | Seed | $1.1M | $36.7M | 2015 |
| Exosite LLC | — | Other Technology | Pre-Seed | $675K | $15.9M | 2009 |
| Tychon Biosciences LLC | — | Biotech / Pharma | Pre-Seed | $671K | $10.2M | 2015 |
| Steady State Imaging LLC | — | Other Health Care | Pre-Seed | $550K | $7.7M | 2008 |
| Invenshure Fund II, LP | — | Other Technology | Pre-Seed | $456K | $19.3M | 2015 |
Troy D. Kopischke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Troy D. Kopischke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Danny J. Cunagin | 10 | 10 |
| Mark E. Sylvester | 3 | 3 |
| Danny Cunagin | 2 | 2 |
| Mark J. Sylvester | 2 | 2 |
| Troy Kopischke | 2 | 2 |
| Jeremy D. Friese | 2 | 2 |
| Paul Meister | 1 | 12 |
| Francisco Gimenez | 1 | 7 |
| William Blake | 1 | 5 |
| Marijn Dekkers | 1 | 4 |
| James Olson | 1 | 4 |
| Andrew M. Weiss | 1 | 3 |
| Jim Olson | 1 | 3 |
| Mark Sylvester | 1 | 3 |
| Jeremy L. Friese | 1 | 3 |
| Brent Backhaus | 1 | 2 |
| Fred B. Parks | 1 | 2 |
| Colby Moosman | 1 | 2 |
| Jill Davies | 1 | 2 |
| Constantine G. Pantelis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.